Kestra Advisory Services, LLC Lipocine Inc. Transaction History

Kestra Advisory Services, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 31, 2023	BUY	$0.37 - $8.65 $2,818 - $65,895	7,618 Added 2.76%	283,918 $113,000
Q3 2022 Nov 01, 2022	BUY	$0.49 - $7.65 $735 - $11,475	1,500 Added 0.55%	276,300 $124 Million
Q2 2022 Aug 12, 2022	SELL	$0.73 - $1.34 $23,725 - $43,550	-32,500 Reduced 10.58%	274,800 $220,000
Q1 2022 Apr 26, 2022	BUY	$0.89 - $1.85 $59,630 - $123,950	67,000 Added 27.88%	307,300 $421,000
Q4 2021 Jan 20, 2022	SELL	$0.99 - $1.2 $9,026 - $10,941	-9,118 Reduced 3.66%	240,300 $237,000
Q3 2021 Oct 19, 2021	BUY	$1.08 - $1.49 $193,771 - $267,332	179,418 Added 256.31%	249,418 $271,000
Q2 2021 Jul 28, 2021	BUY	$1.17 - $1.59 $81,900 - $111,300	70,000 New	70,000 $98,000
Q1 2021 May 10, 2021	SELL	$1.38 - $2.28 $477,642 - $789,149	-346,118 Closed	0 $0
Q4 2020 Jan 20, 2021	BUY	$1.2 - $1.69 $415,341 - $584,939	346,118 New	346,118 $453 Million

Ticker LPCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,510,800
Market Cap $431M
Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...

Get notified when there are updates to the investment portfolio of Kestra Advisory Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Kestra Advisory Services, LLC with notifications on news.